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Abstract
Background: Coronary bifurcation lesions pose therapeutic problems during percutaneous coronary 
interventions. The aim of this study was to analyze the strategy of coronary bifurcation treatment and 
associated angiographic as well as clinical outcomes in a large hospital in Northern Poland.
Methods: Between January 2012 and January 2014 patients with stable coronary artery disease or 
non-ST-elevation acute coronary syndrome (NSTE-ACS) were treated with regular drug-eluting stents 
(rDES) or dedicated bifurcation stents (BiOSS Expert® or BiOSS LIM®). Clinical and angiographic 
controls were planned at 12 months. The primary endpoint was major adverse cardiovascular events 
(MACE) rate composed of cardiac death, myocardial infarction, and target lesion revascularization 
(TLR) at 12 months.
Results: In total, 152 patients were enrolled in whom 158 stents were deployed (99 BiOSS stents and 
59 rDES). Left anterior descending artery (50%) was the dominant target vessel followed by left circum-
flex (25%). There was no stent implantation failure. In 10 (6.3%) patients rDES was required within 
the side branch. At 12 months MACE rate was 11.2%, whereas TLR rate was 7.9%. In the logistic 
regression analysis final kissing balloon technique was the prognostic factor for better clinical outcome, 
whereas NSTE-ACS and true bifurcations were risk factors of a poor outcome.
Conclusions: Percutaneous coronary bifurcation treatment is a safe and effective procedure, and pro-
visional T-stenting is the preferred technique. Both rDES as well as dedicated bifurcation stents enabled 
a simple and fast bifurcation treatment option with comparable MACE and TLR rates. (Cardiol J 2017; 
24, 6: 589–596)
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Introduction
Coronary bifurcation lesions pose a therapeu-
tic challenge and are linked with higher rates of 
periprocedural complications as well as higher rates 
of in-stent restenosis and stent thrombosis [1]. 
Presently, provisional T-stenting (PTS) is the best 
approach [2, 3]. However, the optimal strategy for 
coronary bifurcations treatment remains a subject 
of debate, mainly when the side branch (SB) is 
large, not easily accessible or narrowed by a long 
lesion [4–7]. 
The aim of this study was to analyze the 
strategy for coronary bifurcation lesion treatment 
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and associated clinical as well as angiographic 
outcomes in a large hospital in Northern Poland.
Methods
Study population and study plan
It was a prospective registry conducted be-
tween January 2012 to January 2014 in a high-
volume center (> 1500 percutaneous coronary 
intervention [PCI] per year) in Poland (Olsztyn). 
Patients with stable coronary artery disease (CAD) 
or non-ST-segment elevation acute coronary syn-
drome (NSTE-ACS) were considered eligible for 
enrollment. The inclusion criteria were: age ≥ 18 
years old, de novo coronary bifurcation lesion (in-
cluding unprotected left main), main vessel (MV) 
diameter ≥ 2.5 mm and SB diameter ≥ 2.0 mm 
assessed by visual estimation. Main exclusion 
criteria were: ST-elevation myocardial infarction 
(STEMI), inability to take dual antiplatelet therapy 
for 12 months, left ventricular ejection fraction ≤ 
30% as well as lack of written informed consent. 
Institutional Review Board approved the study 
protocol. 
Interventional procedure  
and concomitant medications
Procedures were performed by six independ-
ent operators. Single stent implantation in the 
proximal MV-distal MV across SB was the default 
strategy in all patients (PTS). Bifurcation lesions 
were assessed according to Medina classification 
using an index of 1 for stenosis greater than 50% 
and 0 for no stenosis (visual estimation). There was 
no restriction regarding lesion length in patient 
selection. The main indication for using dedicated 
bifurcation stents was the ratio of proximal MV 
diameter to distal MV diameter > 1.2. If required, 
additional regular drug-eluting stents (rDES) were 
implanted. A stent in SB was implanted only if 
proximal residual stenosis was greater than 70% 
after balloon dilatation and/or significant flow 
impairment after proximal MV-distal MV stenting 
and/or a flow limiting dissection were noted. The 
implantation protocol was as follows: 
1. Wiring of both branches;
2. MV predilatation and/or SB predilatation ac-
cording to the operator’s decision; 
3. Stent implantation (inflation for at least 20 s); 
4. Proximal optimization technique (POT) at 
operator’s discretion;
5. SB postdilatation/stent implantation if necessary;
6. Final kissing balloons (FKB) inflation at opera-
tor’s discretion.
In patients with NSTE-ACS, a loading dose of 
clopidogrel (600 mg), ticagrelor (180 mg) or prasu-
grel (60 mg) was given, and, if needed, also a load-
ing dose of acetylsalicylic acid (ASA) was applied 
(300 mg). In planned procedures, 72 h before PCI 
each patient received ASA (75 mg/24 h) and clopi-
dogrel (75 mg/24 h). All procedures were performed 
in a standard way via radial or femoral access using 
6 Fr or 7 Fr guiding catheters. After insertion of the 
arterial sheath each patient received unfractionated 
heparin (70–100 IU/kg). Additional bolus was given 
to maintain an activated clotting time > 250 s. 
Dual antiplatelet therapy (ASA 75 mg q.d. and clopi-
dogrel 75 mg q.d., prasugrel 10 mg q.d. or ticagrelor 
90 mg b.i.d.) was prescribed for 12 months.
All patients had troponin I (TnI), creatinine ki-
nase (CK) and CK-MB levels examined before the 
procedure, 6 h and 24 h thereafter. Periprocedural 
myocardial infarction (MI) (type 4a) was assessed 
according to the third universal definition [8]. 
Device description
All drug-eluting stents available in the cathlab 
could have been used. In this study there were regular 
paclitaxel-eluting stents LucChopin2 with strut thick-
ness of 120 µm, sirolimus-eluting stents Alex with 
strut thickness of 70 µm or Cre8 with strut thickness 
of 80 µm and everolimus-eluting stents Xience with 
strut thickness of 81 µm and two dedicated bifurcation 
stents: paclitaxel-eluting BiOSS Expert® with strut 
thickness of 120 µm and sirolimus-eluting BiOSS 
LIM® with strut thickness of 120 µm [9, 10].
Follow-up
Clinical follow-up was performed with office 
visits or telephone contact at 12 months after 
intervention. Adverse events were monitored 
throughout the study period. Follow-up coronary 
angiography was performed at 12 months unless 
clinically indicated earlier.
Endpoints
The primary endpoint was the cumulative rate 
of major adverse cardiovascular events (MACE) 
including cardiac death, MI and repeated revascu-
larization of the target lesion (TLR). The secondary 
endpoints included cardiac death, all-cause death, 
MI, TLR and late lumen loss (LLL). All deaths were 
deemed cardiac unless proven otherwise. 
Angiographic analysis 
All angiograms were recorded after intracoro-
nary administration of nitroglycerin (200 µg). Two 
orthogonal views were chosen to visualize the 
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target lesion. A quantitative coronary angiography 
(QCA) was performed using dedicated bifurcation 
software CAAS version 5.9 (2D analysis). Catheter 
calibration was performed in all cases. The proxi-
mal main vessel (the artery before SB take-off), the 
distal main vessel (artery beyond the ostium of SB), 
and the SB (the smaller vessel at the point of vessel 
divergence) were analyzed separately — subseg-
mental QCA analysis was performed according to 
European Bifurcation Club (EBC) Consensus [11]. 
The following parameters were calculated: lesion 
length, reference vessel diameter (RVD), mini-
mal lumen diameter (MLD), % diameter stenosis 
(%DS), acute lumen gain and LLL before and after 
stent implantation and/or on follow-up. All refer-
ence diameters were measured 5 mm from the end 
of angiographically visible plaque in all 3 segments 
of bifurcation without use of interpolations (user 
defined reference diameters). Percent diameter 
stenosis (using parameters from each segment) 
was measured for each vessel segment separately 
using the following formula: %DS = [1 – (MLD/ 
/RVD)] × 100% [12]. 
Statistical analysis
Continuous variables were presented as mean 
± standard deviation. Categorical data were pre-
sented as numbers (%). Continuous variables were 
compared using an unpaired Student t test, and 
categorical data using the c2 test or Fisher exact 
test, as appropriate. If distribution was not normal, 
Wilcoxon signed-rank tests and Mann-Whitney 
U-tests were used. P values of < 0.05 were con-
sidered statistically significant. Also, univariate 
and multivariate logistic regression analyses were 
performed. Statistical analysis was performed us-
ing R 3.0.2 for OS (R Foundation, Vienna, Austria).
Results
Baseline clinical characteristics
Between January 2012 and January 2014, 
a total of 152 patients were enrolled of whom 158 
coronary bifurcation lesions were treated. The 
mean age was 62.6 ± 9.11 years and women had 
a share of 26.3% in the population. Most patients 
had stable CAD (67.1%), arterial hypertension 
(82.2%) and dyslipidemia (88.2%). The detailed 
data are presented in Table 1.
Angiographic and procedural characteristics
The bifurcation lesions were most frequently 
located in left anterior descending artery; 50%; 
Fig. 1A), and true bifurcations (Medina type 1,1,1; 
Table 1. Demographics (n = 152).
No. of patients (%) 
Age 62.6 ± 9.11
Women 40 (26.3%)
Stable CAD 102 (67.1%)
NSTE-ACS 50 (32.9%)
Hypertension 125 (82.2%)
Dyslipidemia 134 (88.2%)
Diabetes type 2 43 (28.3%)
Prior MI 65 (42.8%)
Prior PCI 68 (44.7%)
Coronary artery bypass graft 16 (10.5%)
Lower extremity artery disease 12 (7.9%)
Carotid artery disease 6 (3.9%)
Chronic kidney disease 12 (7.9%)
Smoking 54 (35.5%)
CAD — coronary artery disease; NSTE-ACS — non-ST-elevation 
acute coronary syndrome; MI — myocardial infarction; PCI —  
percutaneous coronary intervention
Figure 1. A. Lesion location; B. Late lumen loss in mm; 
LAD — left anterior descending artery; LCx — left cir-
cumflex artery; LM — left main coronary artery; RCA —  
right coronary artery; MB — main branch; MV — main 
vessel; SB — side branch.
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1,0,1 or 0,1,1) stand for 102 (64.6%) treated le-
sions. Only DES were deployed among which 
most frequently dedicated bifurcation stents were 
used (n = 99, 62.7%), followed by rDES (n = 59, 
37.3%) (Table 2).
The main procedural aspects are presented in 
Table 3. All stents were successfully implanted. In 
10 cases the additional stent was implanted into the 
SB, mainly using T-and-protrusion (TAP) or culotte 
techniques. In the dedicated bifurcation stent sub-
group SB was stented in 4 (4.04%) cases due to 
significant stenosis and large diameter, whereas in 
regular DES 6 (10.2%) cases were registered due 
to significant stenosis in a large SB (n = 4) or due 
to flow limiting dissection (n = 2). Final kissing 
balloon was applied in 24.1% of procedures.
Clinical outcomes
There were 5 (3.2%) cases of periprocedural 
MI due to transient SB occlusion. Additionally, 
there were 9 (5.7%) cases of in-hospital increase of 
TnI level (max 1.8 ng/mL) — however, they were 
asymptomatic/without electrocardiogram changes 
which did not require repeated angiography (MI 
type 4a criteria not met).
Clinical follow-up data at 12 months were avail-
able in all patients (Table 4). The MACE incidence 
was 11.2% (n = 17) and it was similar between the 
dedicated bifurcation stent subgroup and the regular 
DES subgroup, 11.5% and 10.5%, respectively. There 
were 5 cardiac deaths, in which 4 were sudden cardiac 
deaths and one death was caused by complications 
of MI. The TLR rate was 7.9% (n = 12). No definite 
in-stent thrombosis was registered, but one cannot 
exclude in-stent thrombosis since there were 4 sud-
den cardiac deaths. Further analyses are presented 
as Supplementary Table 1 and 2 (see journal 
website) — they describe clinical outcomes in dia-
betic and left main subgroups, respectively.
Quantitative coronary angiography analysis
Angiographic follow-up at 12 months was 
available in 78 (51.3%) patients, of whom 34 had 
BiOSS Expert® stent implanted, 28 — BiOSS LIM® 
and 16 — regular DES. The late lumen loss values 
in separate segments of coronary bifurcation are 
presented in the Figure 1B. Similar LLL values 
were obtained in rDES and BiOSS LIM® groups, 
Table 2. Lesion and stent characteristics (n = 158).
Lesion characteristics No. of lesions
(%)
Medina type
1.1.1. 34 (21.5%)
1.1.0. 22 (13.9%)
1.0.1. 32 (20.2%)
0.1.1. 36 (22.8%)
1.0.0. 21 (13.3%)
0.1.0 13 (8.2%)
Lesion type
A 0 (0%)
B1 76 (48.1%)
B2 50 (31.6%)
C 32 (20.3%)
Stent type
Regular DES: 59 (37.3%)
Paclitaxel eluting DES 18 (11.4%)
Sirolimus eluting DES 19 (12.0%)
Everolimus eluting DES 22 (13.9%)
Dedicated bifurcation stent: 99 (62.7%)
BiOSS Expert (paclitaxel eluting) 20 (12.7%)
BiOSS LIM (sirolimus eluting) 79 (50%)
DES — drug eluting stent
Table 3. Procedural characteristics (n = 158).
Parameter No of lesions  
(%)
Successful implantation 158 (100%)
Main vessel predilatation 130 (82.3%)
Side branch predilatation 115 (72.8%)
Both branches predilatation 6 (3.8%)
Regular DES nominal  
parameters [mm]
3.15 ± 0.60 × 
20.69 ± 8.81
Dedicated bifurcation stent  
nominal parameters  
(proximal diameter x distal  
diameter x length) [mm]
3.63 ± 0.36 ×  
2.95 ± 0.35 × 
18.42 ± 3.34
Side branch postdilatation 38 (24.1%)
Proximal optimization technique 7 (4.4%)
Final kissing balloon 38 (24.1%)
Additional stent in side branch 10 (6.3%)
Fluoroscopy time [min] 12.5 ± 8
Contrast volume [mL] 161 ± 93
Vascular access femoral/radial 7%/93%
Guiding catheter 6 F/7 F 100%/0%
Double-stent technique: n = 10 (%)
T-stenting 1 (10%)
TAP 4 (40%)
Mini-crush 1 (10%)
Culotte 4 (40%)
DES — drug-eluting stent; TAP — T-and-protrusion technique
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whereas BiOSS Expert® group characterized 
a slightly larger neointima growth. Also, when com-
paring LLL value significant differences in proximal 
MV and in distal MV, but not in SB, were observed. 
Logistic regression analysis
Results of logistic regression analyses are pre-
sented in Table 5 and Table 6 for MACE and TLR, 
respectively. Regarding MACE rate, NSTE-ACS 
and true bifurcation were associated with worse 
clinical outcome, whereas FKB was associated 
with better clinical outcome. Similar results were 
obtained when the TLR rate was analyzed.
Discussion
The main findings of this study are: 1) coronary 
bifurcations were mainly treated with 1 stent (PTS 
Table 4. Clinical results.
Whole population (n = 152) DBS (n = 95) Regular DES (n = 57)
MACE 17 (11.2%) 11 (11.5%) 6 (10.5%)
All-cause death 9 (5.9%) 5 (5.3%) 4 (7.0%)
Cardiac death 5 (3.3%) 2 (2.1%) 3 (5.3%)
Myocardial infarction 5 (3.3%) 3 (3.2%) 2 (3.5%)
Stent thrombosis 0 (0%) 0 (0%) 0 (0%)
Target lesion revascularization 12 (7.9%) 7 (7.4%) 5 (8.8%)
MACE — major adverse cardiovascular events; DBS — dedicated bifurcation stents; DES — drug eluting stent
Table 5. Logistic regression for major adverse cardiovascular events.
Variate Univariate analysis Multivariate analysis 
OR (95% CI) P OR (95% CI) P
BiOSS vs. DES 0.918 (0.547–1.247) 0.547
BiOSS Expert vs. DES 1.111 (0.650–1.831) 0.568
BiOSS LIM vs. DES 0.714 (0.665–1.120) 0.341
Sex: female vs. male 0.747 (0.670–1.123) 0.789
Age [increase per 1 year] 0.814 (0.684–1.336) 0.238
NSTE-ACS 2.180 (1.560–2.446) 0.008 1.801 (1.391–3.150) 0.044
Arterial hypertension 1.361 (0.775–2.562) 0.345
Diabetes mellitus 1.254 (0.881–1.565) 0.258
Dyslipidemia 1.127 (0.454–1.665) 0.456
Prior MI 1.742 (0.910–2.774) 0.412
Prior PCI 1.113 (0.712–1.975) 0.651
Coronary artery bypass graft 1.343 (0.763–3.129) 0.345
Chronic kidney disease 1.232 (0.447–2.002) 0.782
Smoking 1.468 (0.751–1.802) 0.753
True bifurcation 2.279 (1.114–4.751) 0.021 1.758 (1.114–2.452) 0.035
LM bifurcation 1.238 (1.110–3.272) 0.019 1.831 (0.893–2.318) 0.441
MV predilatation 1.701 (1.443–3.678) 0.009
SB predilatation 1.315 (0.822–2.215) 0.245
SB stenting 1.360 (0.985–2.642) 0.348
Final kissing balloon 0.501 (0.396–0.950) 0.038 0.401 (0.246–0.820) 0.021
Proximal optimization technique 1.101 (0.656–1.352) 0.392
OR — odds ratio; CI — confidence interval; DES — drug eluting stents; NSTE-ACS — non-ST-elevation acute coronary syndrome; MI — myo-
cardial infarction; PCI — percutaneous coronary intervention; LM — left main; MV — main vessel; SB — side branch
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strategy), 2) 1-year MACE and TLR rates were 
11.2% and 7.9%, respectively, 3) clinical outcomes 
for dedicated bifurcation stents BiOSS and regu-
lar DES were similar, 4) optimization techniques 
(FKB, POT) were rarely used.
In this study the population was severely 
diseased, with rates of diabetes (28.3%), prior MI 
(42.8%) and prior PCI (44.7%) which is higher than 
in other studies assessing bifurcation treatment, 
11–25.7%, 19.5–46% and 11.3–37.1% [13–17] 
respectively.
In recent years, a series of studies helped to 
characterize the coronary bifurcation anatomy, 
and geometric relations linking MV and SB were 
expressed as mathematical models such as Mur-
ray’s, Finet’s or Huo-Kassab’s laws [13, 14, 18]. 
To some extent as a result, EBC recommends PTS 
as the standard strategy for treatment of coronary 
bifurcation. Although there are lesions for which 
PTS is not the optimal approach, the need for 
an alternative strategy is relatively rare in most 
cases [11]. Results obtained in this registry were 
concordant with these recommendations. Almost 
all bifurcations (93.7%) were treated with PTS 
strategy, and what is important is that 64.5% of 
cases were true bifurcations. As proven earlier, 
PTS strategy ensured the best angiographic and 
clinical outcomes in the majority of studies [11]. 
Moreover, Kim et al. [15] as well as others showed 
that a 1-stent technique was better than a 2-stent 
technique [15, 16].
Only 10 cases required a two-stent technique, 
mainly performed with TAP and culotte. Worth 
stressing is the fact that all culotte procedures 
were performed in distal left main with the de-
ployment of two BiOSS LIM® stents as described 
previously [17]. 
Predilatation of MV prior to stenting is the 
common approach, whereas routine SB dilation 
is unnecessary. Nevertheless, in the presence of 
severe SB ostial stenosis it should be considered. 
We performed MV predilatations in 82.3% cases 
and SB predilatations in 72.8%. We had in mind 
that potential advantages of SB dilatation include 
Table 6. Logistic regression for target lesion revascularization.
Variate Univariate analysis Multivariate analysis
OR (95% CI) P OR (95% CI) P
BiOSS vs. DES 1.018 (0.537–1.237) 0.623
BiOSS Expert vs. DES 1.211 (0.609–2.001) 0.755
BiOSS LIM vs. DES 0.814 (0.615–1.760) 0.188
Sex: female vs. male 0.647 (0.450–0.993) 0.046
Age [increase per 1 year] 0.694 (0.523–1.416) 0.623
NSTEMI/UA 2.080 (1.640–3.566) 0.007 1.921 (1.231–3.120) 0.004
Arterial hypertension 1.411 (0.675–3.102) 0.212
Diabetes mellitus 1.244 (0.651–1.675) 0.498
Dyslipidemia 1.317 (0.732–1.455) 0.578
Prior MI 1.412 (0.830–2.414) 0.243
Prior PCI 1.223 (0.872–2.275) 0.878
Coronary artery bypass graft 1.523 (0.863–2,729) 0.465
Chronic kidney disease 1.412 (0.767 - 2.122) 0.619
Smoking 1.218 (0.751–1.802) 0.773
True bifurcation 2.339 (1.324–3.671) 0.019 1.988 (1.442–4.172) 0.031
LM bifurcation 1.328 (1.115–3.672) 0.042 1.421 (0.893–2.218) 0.655
MV predilatation 1.211 (1.013–3.128) 0.032
SB predilatation 1.215 (0.782–1.785) 0.166
SB stenting 1.210 (0.765–3.542) 0.174
Final kissing balloon 0.721 (0.496–0.980) 0.037 0.798 (0.226–0.960) 0.041
Proximal optimization technique 0.941 (0.508–1.122) 0.534
OR — odds ratio; CI — confidence interval; DES — drug eluting stents; NSTEMI/UA — non-ST-elevation myocardial infarction/unstable angina; 
MI — myocardial infarction; PCI — percutaneous coronary intervention; LM — left main; MV — main vessel; SB — side branch
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increased ostial SB lumen, facilitated rewiring of 
the SB after stenting and avoiding rewiring and 
post-dilatation of the SB after implantation of the 
MV stent [19].
Appropriate stent apposition in the proximal 
MV is achieved by POT, which is performed by 
dilating the proximal MV stent from the proximal 
stent edge to just proximal to the carina, using 
a short oversized balloon. POT facilitates SB access, 
reduces risk of accidental abluminal rewiring, low-
ers the risk of stent distortion by catheter collision, 
and enhances scaffolding at the SB ostium. Thus, 
POT should be considered a standard step in the 
bifurcation treatment. Also, FKB is the technique 
which optimizes the procedure [11]. Unfortunately, 
in our paper rates of POT and FKB were low, 
4.4% and 24.1%, respectively. This could have 
been caused by the fact that only recently POT is 
strongly recommended by EBC, and in case of FKB 
— that only rarely a 2-stent technique was used 
where FKB is obligatory. Also, in 62.7% of cases 
dedicated bifurcation BiOSS stents were implanted. 
Theoretically, the stepped design of the BiOSS® 
delivery balloon was to ensure FKB- and POT- 
-like effects, thus allowing operators to frequently 
omit this part of the procedure. However, opera-
tors firmly believed that the BiOSS® construction 
ensures those effects. As was shown in POLBOS I 
trial the lack of FKB/POT was associated with the 
worse clinical outcome and the trend in larger late 
lumen loss values, whereas in the NORDIC 3 study 
it was proved that FKB reduced angiographic side 
branch restenosis, especially in patients with true 
bifurcation lesions [20, 21]. These findings were 
confirmed in the MITO Registry [22]. Also worth 
stressing, is the fact that the negative impact of 
true bifurcation and positive impact of FKB on 
MACE and TLR rates were also confirmed in the 
present logistic regression analyses.
Nevertheless, the results obtained in the men-
tioned registry (MACE 11.2%, TLR 7.9%) were 
comparable or even better than in other clinical 
trials assessing coronary bifurcation treatment 
such as POLBOS I [21], POLBOS II [23] or EBC 
TWO [24].
As a kind of innovation in this study dedi-
cated bifurcation stents were used. As was already 
mentioned dedicated bifurcation stents were used 
in 62.7% of cases. In recent years bifurcation 
dedicated stents were developed but majority of 
them did not enter routine clinical practice. In the 
Tryton trial, 704 patients with non-left main, true 
coronary bifurcation lesions were randomized to 
a Tryton-facilitated culotte technique or to a PTS with 
an everolimus-eluting stent [25]. At 9 months, the 
primary endpoint (target vessel failure) was 17.4% 
in the Tryton group compared with 12.8% in the 
PTS group. Obtained results showed that safety and 
efficacy reached by PTS with the latest-generation 
DES make the role of dedicated stents for non-left 
main lesions quite limited. Based on this, the EBC 
consensus was in favor of considering distal left main 
treatment due to its specific anatomic complexity, 
which at least in theory may benefit from technical 
improvements of dedicated stents [11]. This position 
is supported by published reports [9, 26–28]. 
Limitations of the study
This registry has several limitations that 
should be acknowledged. First of all the sample size 
was relatively small and no sample size calculation 
was performed. Other limitations of this study 
are its non-randomized manner as well as other 
drawbacks of registry studies. Also, the variety of 
rDES use, the lack of intravascular ultrasound, use 
and the relatively low diabetes type 2 rate could be 
treated as drawbacks.
Conclusions
Percutaneous coronary bifurcation treatment 
is safe and effective procedure, and provisional 
T-stenting is the preferred technique. Both regular 
DES as well as dedicated bifurcation stents BiOSS 
Expert® and BiOSS LIM® enabled a simple and fast 
bifurcation treatment option with a single stent and 
with comparable MACE and TLR rates.
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